Nu Skin Provides Estimated Second Quarter Revenue
|
page 2
|
• |
issues that could arise during the company's closing and review/audit procedures, such as the need to make an adjustment to the preliminary numbers;
|
• |
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
|
• |
adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
|
• |
risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that
results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions,
imposition of fines, or any other adverse actions or events;
|
• |
any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained
basis;
|
• |
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
|
• |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations
and results;
|
• |
risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
|
• |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
• |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory
write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
Nu Skin Provides Estimated Second Quarter Revenue
|
page 3
|
• |
regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if
the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
|
• |
unpredictable economic conditions and events globally, including trade policies and tariffs;
|
• |
the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United
States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
|
• |
continued competitive pressures in the company's markets.
|